Subscribe
Logo small
Search

Better access to innovative therapies in IBD will optimize system spending. Doctors and patients expect relaxation of inclusion criteria

MedExpress Team

Piotr Wójcik

Published Nov. 21, 2023 18:20

Better access to innovative therapies in IBD will optimize system spending. Doctors and patients expect relaxation of inclusion criteria - Header image
fot. Piotr Wójcik
With the increasing availability of innovative therapies for inflammatory bowel diseases under drug programs, the Social Security Administration's per capita spending on disability benefits, especially pensions, is falling. This is the main conclusion of the report compiled by MAHTA. The problem, however, continues to be strict inclusion criteria and poor pricing. As a result, the most effective treatment options still benefit a small percentage of patients. There are also regions where treatment is provided by single reference centers.

Inflammatory bowel diseases, namely Crohn's disease and ulcerative colitis, are chronic diseases of the gastrointestinal tract characterized by a high level of inconvenience, not least because of their symptoms, which include debilitating, often bloody diarrhea, malnutrition or very severe abdominal pain, as well as complications such as perianal fistulas, which are very difficult to heal.

- Feelings of shame, related to the nature of these symptoms, are also a problem. Patients find it difficult to talk about them. People with the disease often hide the disease, but at the same time they want to have children, start a family, and work," says Professor Jaroslaw Regula, head of the Clinical Gastroenterology Clinic at the National Cancer Institute in Warsaw.

- The available treatment...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie o pracę za darmo

Lub znajdź wyjątkowe miejsce pracy!

Read also